Metis TechBio stock

7666 · HKEX · HKD

Compare Metis TechBio
$6.65Change from previous close: −9.53%Absolute change: −$0.70

Close · November 20, 2026

Price history

−69.38% over the period

Full history: from $21.70 (May 15, 2026) to $6.65 (November 20, 2026), −69.38%.

Show chart data

Closing prices adjusted for splits: one row per trading day.

DateClose
November 20, 2026$6.65
November 13, 2026$8.36
November 6, 2026$10.99
October 30, 2026$11.15
October 23, 2026$10.58
October 16, 2026$11.92
October 9, 2026$14.57
October 2, 2026$18.52
September 25, 2026$15.61
September 18, 2026$17.40
September 11, 2026$15.42
September 4, 2026$13.82
August 28, 2026$13.88
August 21, 2026$14.24
August 14, 2026$12.11
August 7, 2026$11.12
July 31, 2026$10.06
July 24, 2026$11.25
July 17, 2026$10.11
July 10, 2026$12.48
July 3, 2026$13.93
June 26, 2026$13.05
June 18, 2026$14.41
June 12, 2026$13.19
June 5, 2026$14.06
May 29, 2026$14.78
May 22, 2026$16.88
May 15, 2026$21.70

At a glance

  • The company

    Develops AI-driven nanomaterials and NanoForge technologies for delivering active agents in pharmaceutical and biotech research

  • Latest results

    Quarter to June 30, 2026 · EPS -¥0.17

TickerLandia's take on Metis TechBio

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$6.87
52-wk high$29.98

−77.84% from the 52-week high

Analysts · 4 analysts

Average target$24.63+270.71% vs. price

Buy 4 · Hold 0 · Sell 0

TickerLandia Fingerprint: Metis TechBio

Compared with similar companies: very weak momentum, very high risk, and very low earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Metis TechBio is cheaper than similar companies

Metis TechBio's Price/book: 2.45, −47% against the median of a group of 11 similar companies (4.64).

Compared with 11 similar companies

Metis TechBio's metrics compared with similar companies
MetricMetis TechBioPosition in the groupBand
Operating margin-131.2%Low
ROE229.5%High
Debt/equity0.06Middle
Price/book2.45Low
Net margin-137.0%Low

Grey band: the middle half of the group; tick: the median; dot: Metis TechBio. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥77.15M

Latest quarter · Q2 2026

Net income

-¥76.6M

Latest quarter · Q2 2026

Quarterly net margin

-99.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$8.69B
EPS
-$0.38
Volume
15.23M
Daily trading
€7.82M
Dividend yield
0.00%

How Metis TechBio is changing

All results
  • Revenue grew 474.4% a year on average over the last 3 years

  • Operating margin rose from −68,012.5% to −356.6%

  • Shares outstanding down 20.9% in 3 years

Returns

Metis TechBio returns

PeriodMetis TechBioHang Seng$1,000 becomes
1 month−40.62%−6.10%$594
6 months−63.08%−12.63%$369

Over the last 6 months it has done better than 3% of the stocks in the Materials sector.

Price only, without dividends.

The chart in detail

Metis TechBio: technical analysis

The price is 73.7% below its all-time closing high ($25.24, May 14, 2026).

RSI (14 sessions)
24
Below 30: a strong fall in a short time
vs 50-session average
−48.47%

Active signals

  • Close below the low of the previous 55 sessions.

  • RSI below 30: the stock has fallen a lot in a short time.

    since November 17, 2026

Support and resistance

Price areas where Metis TechBio has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$12.29+84.88%2 touches, last on October 29, 2026
  2. Resistance$11.56+73.89%4 touches, last on November 10, 2026
  3. Resistance$9.74+46.56%4 touches, last on November 3, 2026
  4. Last price$6.65
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the Hang Seng.

Beta (1 year) vs Hang Seng
1.88
Volatility (60 sessions, annualised)
109.2%
Largest fall in the last year
−73.67%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Metis TechBio and its competitors

Metis TechBio develops AI-driven nanomaterial tools for delivering active agents across carbon-based life forms, with research work in Chinese Mainland and the United States. Its NanoForge suite pairs a lipid compound collection with machine-learning models, molecular simulation and automated screening systems. Further platforms named AiTEM, AiLNP and AiRNA model how nanoscale particles interact, supporting the design, optimization and validation of nanomaterials and their payloads.

Headquarters
Beijing, China
Employees
150
Founded
2020
Chief executive
Tsai-Ta Lai
Metis TechBio and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Metis TechBio7666$1.11B-131.2%—−63.08%
MesoblastMSB$1.48B-42.6%—−14.82%
Neuren PharmaceuticalsNEU$1.83B19.9%144.0+68.84%
InSilico Medicine Cayman TopCo3696$2.59B-6.9%—−36.46%
Telix PharmaceuticalsTLX$2.92B6.2%92.3−7.71%
3SBio1530$4.56B60.3%3.90−34.08%

Same industry or related industries, similar size. Compare Metis TechBio with its competitors · Full profile